Opthea Limited (ASX:OPT)
Australia · Delayed Price · Currency is AUD | Market Cap | 738.77M +61.5% |
| Revenue (ttm) | -20.12K -43.3% |
| Net Income | 296.97M |
| EPS | 0.23 |
| Shares Out | 1.23B |
| PE Ratio | 2.59 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,141,489 |
| Average Volume | 5,974,614 |
| Open | 0.6050 |
| Previous Close | 0.6000 |
| Day's Range | 0.5950 - 0.6150 |
| 52-Week Range | 0.3350 - 1.1650 |
| Beta | 1.53 |
| RSI | 21.86 |
| Earnings Date | May 29, 2026 |
About Opthea
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea... [Read more]
Financial Performance
In fiscal year 2025, Opthea's revenue was 222,694, a decrease of -43.29% compared to the previous year's 392,686. Losses were -248.31 million, -24.78% less than in 2024.
Financial StatementsNews
Opthea Transcript: AGM 2025
The AGM covered director re-elections, adoption of the remuneration report, and approval of option grants, with all resolutions put to a poll and no questions raised by shareholders. Voting results will be published post-meeting.
Opthea Transcript: Investor Update
Phase III trials failed to show efficacy for sozinibercept in wet AMD, leading to program termination and a settlement with investors that leaves the company with $20 million cash and no debt. A strategic review is underway to explore internal and external opportunities, with updates expected later this year.
Opthea Provides Corporate Update
Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to contin...
Opthea Announces Decision to Discontinue Wet AMD Trials
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on t...
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., ...
Opthea Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
Sozinibercept, a VEGF-C/D trap, is advancing through Phase 3 trials for wet AMD, targeting improved vision outcomes in combination with anti-VEGF-A agents. Pivotal data readouts are imminent, with strong market, payer, and physician support, and a potential FDA approval by late 2026.
Opthea to Present at Oppenheimer Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therap...
Opthea Wet AMD Data Featured at Macula Society Meeting
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Transcript: Investor Day 2025
Sozinibrecept is positioned as a first-in-class combination therapy for wet AMD, with pivotal phase 3 data expected in 2024 and potential FDA approval by end of 2026. The product targets a $7B+ U.S. market, offers robust clinical differentiation, and is supported by a strong commercial team and favorable payer feedback.
Opthea Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025
Sozinibercept, a first-in-class VEGF-C/D trap, has shown superior vision outcomes in wet AMD and is in two pivotal Phase III trials with top-line data expected in 2024. The company is well-funded, targeting a 2026 BLA submission, and preparing for a U.S. launch.
Opthea to Host Investor Days in New York and Australia
Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on Februar...
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia an...
Opthea Transcript: Citi's 2024 Global Healthcare Conference
Three late-stage ophthalmology assets are advancing toward commercialization, each with distinct mechanisms and market strategies. LENZ targets presbyopia with a daily eye drop, Aldeyra offers rapid relief for dry eye and allergy, and Opthea aims to improve wet AMD outcomes by blocking VEGF-C/D.
Opthea's Wet AMD Program to be Featured at FLORetina 2024
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Appoints Kathy Connell to Board of Directors
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J.,...
Opthea Wet AMD Program to be Presented at Innovate Retina
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Transcript: UBS Virtual Ophthalmology Day Conference
Sozinibercept, targeting VEGF-C/D, showed superior vision outcomes in phase II-B wet AMD trials when combined with standard care. Two pivotal phase III trials are fully enrolled, with top-line data expected in 2025, and commercial preparations underway.
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 202...
Opthea Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference
Sozinibercept, a novel anti-VEGF-C/D, demonstrated superior vision outcomes in phase II-B and is advancing through two global phase III trials with readouts expected in 2025. The product targets a $10B market, has strong payer and physician interest, and benefits from a robust safety profile.
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024
Sozinibercept, a first-in-class VEGF-C and -D trap, is in late-stage trials aiming to improve vision outcomes for wet AMD patients, with top-line data expected in 2025. The drug targets a $15B market and is positioned for use with any anti-VEGF-A therapy.
Opthea Announces Executive Leadership Changes and Senior Hires
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOU...
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...